Parenchymal lung disease has been reported as a side effect of MEK inhibitors in adults (54), but whether this event was related to the drug itself, to chronic lung disease of prematurity or to a genetic cause is unknown. This evidence concerns the gene MAP2K7 and chronic lung disease.